Main navigation

• Home
• About us
• Medicines
• Research
• Careers
• Responsibility
• Partnering
• Media
  • Corporate reports
  • Facts, products, pipeline
  • Events calendar
  • Media contacts
  • Press releases
  • Photo library
  • Broadcast Centre
• Investors

You are here

• Home

• Media

Here you will find our corporate press releases, details on upcoming events and other useful information for business and financial media.

• Latest news collapse

  • 16 November 2009 BRILINTA Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting: Patients with ST-Segment Elevation Myocardial Infarction and Planned Percutaneous Coronary Intervention (PCI)

    AstraZeneca today announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome (ACS) patients, those with ST Segment Elevation Myocardial Infarction (STEMI). In this setting, ST segment elevation indicates total obstruction of a coronary artery which warrants emergency surgery with angioplasty, a procedure termed primary Percutaneous Coronary Intervention or “PCI,” in order to restore flow, salvage the heart muscle (myocardium) from infarction and reduce mortality.

  • 13 November 2009 Discovery Research Leader Leaves AstraZeneca

    AstraZeneca announced today that Jan M. Lundberg, Executive Vice President, Discovery Research has resigned to pursue other interests outside the company. Jan will step down from his operational role with immediate effect.

  more news

  • previous
  • • 1
    • 2
    • 3
    • 4
    • 5
  • next

  Financial results collapse

  Third Quarter & Nine Months results 2009 announced Thursday, 29 October
  2009.

  • View details of the event
  • View financial calendar

  Photo & video library collapse

  • Here you can download pictures from our photo library
  • Broadcast footage of AstraZeneca products and activities is available from our Broadcast Centre (requires registration)

• Key Facts collapse

  • We are a world leading pharmaceutical company with a world-class biologics capability.
  • We are active in over 100 countries with a growing presence in important emerging markets including China; corporate office in London, UK; and major R&D sites in Sweden, the UK and the US.
  • We employ over 65,000 people (51% in Europe, 32% in the Americas and 17% in Asia, Africa and Australasia).
  • Alongside our commitment to competitiveness and performance, we continue to be led by our core values to achieve sustainable success.
  • More facts about AstraZeneca

  Research & Development collapse

  We focus our research on six disease areas where we believe our skills and experience can make the most difference.

  • Read about our disease area focus
  • Read about our pipeline progress
  • Review our pipeline summary

Not signed in

Page tools

• Print
• Bookmark this page

Share price